RT Journal Article SR Electronic T1 Prothrombotic antiphospholipid antibodies in COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.15.20131607 DO 10.1101/2020.06.15.20131607 A1 Zuo, Yu A1 Estes, Shanea K. A1 Gandhi, Alex A. A1 Yalavarthi, Srilakshmi A1 Ali, Ramadan A. A1 Shi, Hui A1 Sule, Gautam A1 Gockman, Kelsey A1 Madison, Jacqueline A. A1 Zuo, Melanie A1 Woodward, Wrenn A1 Lezak, Sean P. A1 Lugogo, Njira L. A1 Kanthi, Yogendra A1 Knight, Jason S. YR 2020 UL http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131607.abstract AB Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. At the same time, lung histopathology often reveals fibrin-based occlusion of small vessels in patients who succumb to the disease. Antiphospholipid syndrome (APS) is an acquired and potentially life-threatening thrombophilia in which patients develop pathogenic autoantibodies (aPL) targeting phospholipids and phospholipid-binding proteins. Small case series have recently detected aPL in patients with COVID-19. Here, we measured eight types of aPL (anticardiolipin IgG/IgM/IgA, anti-beta-2 glycoprotein I IgG/IgM/IgA, and anti-phosphatidylserine/prothrombin (PS/PT) IgG/IgM) in the sera of 172 patients hospitalized with COVID-19. We detected anticardiolipin IgM antibodies in 23%, anti-PS/PT IgG in 24%, and anti-PS/PT IgM in 18%. Any aPL was present in 52% of patients using the manufacturer’s threshold and in 30% using a more stringent cutoff (≥40 units). Higher levels of aPL were associated with neutrophil hyperactivity (including the release of neutrophil extracellular traps/NETs), higher platelet count, more severe respiratory disease, and lower glomerular filtration rates. Similar to patients with known and longstanding APS, IgG fractions isolated from patients with COVID-19 promoted NET release from control neutrophils. Furthermore, injection of these COVID-19 IgG fractions into mice accelerated venous thrombosis. Taken together, these studies suggest that a significant percentage of patients with COVID-19 become at least transiently positive for aPL and that these aPL are potentially pathogenic.Competing Interest StatementYK has served as a consultant to Surface Oncology and has a pending patent on the use of biogases in cardiovascular disease. The authors have no other financial conflicts to report.Funding StatementThe work was supported by a grant from the Burroughs Wellcome Fund to JSK and grants from the Michigan Medicine Frankel Cardiovascular Center and A. Alfred Taubman Medical Research Institute to YK and JSK.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study complied with all relevant ethical regulations, and was approved by the University of Michigan Institutional Review Board (HUM00179409).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere are no large datasets to deposit. Other data will be made available via correspondence with the authors.